Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT00536120
- Locations
- 🇺🇸
Research Site 1, Fullerton, California, United States
🇺🇸Research Site, Dallas, Texas, United States
🇺🇸Research site, Farmington Hills, Michigan, United States
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- Drug: RTA 402 Dose2Drug: RTA 402 Dose1
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Biogen
- Registration Number
- NCT00535314
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 284
- Registration Number
- NCT00534261
- Locations
- 🇬🇧
Coordinating Research Site, Glasgow, Scotland, United Kingdom
Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 32
- Registration Number
- NCT00531193
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
- Conditions
- Pancreatic NeoplasmsPancreatic Cancer
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 33
- Registration Number
- NCT00529113
- Locations
- 🇺🇸
Rocky Mountain Cancer Center (US Oncology), Denver, Colorado, United States
🇺🇸Cancer Centers of Florida (US Oncology), Ocoee, Florida, United States
🇺🇸Central Indiana Cancer Centers (US Oncology), Indianapolis, Indiana, United States
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
- Conditions
- Lymphoid MalignanciesAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT00529438
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 9
- Registration Number
- NCT00527410
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 54
- Registration Number
- NCT00526812
- Locations
- 🇺🇸
UCLA School of Medicine, Department of Neurology, Los Angeles, California, United States
🇺🇸Baylor University Medical Center: Neuro-Oncology Associates, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Avonex 15 Year Long Term Follow-up Study
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 122
- Registration Number
- NCT00525343
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Jocab's Neurological Institute, Buffalo, New York, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 72
- Registration Number
- NCT00523328
- Locations
- 🇬🇧
Coordinating Research Site, Newcastle, United Kingdom